Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Similar but different: distinct roles for KRAS and BRAF oncogenes in colorectal cancer development and therapy resistance.

Oncotarget - 28 Aug 2015

Morkel Markus, Riemer Pamela, Bläker Hendrik, Sers Christine

Abstract excerpt

Colorectal cancer (CRC) is characterized by recurrent mutations deregulating key cell signaling cascades and providing the cancer cells with novel functional traits. Among the most frequent mutations in CRC are gain-of-function missense mutations in KRAS and BRAF. Oncogenic activation of KRAS and BRAF is mutually exclusive and occurs in approximately 40% and 10% of all CRCs, respectively. Here we summarize...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Colorectal Neoplasms
Share to Disease Progression
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to MAP Kinase Signaling System

Share to Mutation, Missense

Share to Proto-Oncogene Proteins B-raf

Share to Proto-Oncogene Proteins p21(ras)

Share to Stem Cells

Source

Open in PubMed Open full text

Identifiers

PMID: 26299805
DOI: 10.18632/oncotarget.4750
PMCID: PMC4673229

Genes

BRAF
KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Similar but different: distinct roles for KRAS and BRAF oncogenes in colorectal cancer development and therapy resistance.PMID 26299805Read ↗

Targeting BRAF and RAS in Colorectal CancerSemantic proximity Read ↗

Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer.Semantic proximity Read ↗

Recent Updates on the Significance of KRAS Mutations in Colorectal Cancer Biology.Semantic proximity Read ↗

Signaling pathways involved in colorectal cancer: pathogenesis and targeted therapySemantic proximity Read ↗

Targeting KRAS in Colorectal Cancer: A Bench to Bedside Review.Semantic proximity Read ↗

New advances in the clinical management of RAS and BRAF mutant colorectal cancer patients.Semantic proximity Read ↗

The current understanding on the impact of KRAS on colorectal cancer.Semantic proximity Read ↗

BRAF Mutation in Colorectal Cancers: From Prognostic Marker to Targetable MutationSemantic proximity Read ↗

Differential gene expression signatures between colorectal cancers with and without KRAS mutations: Crosstalk between the KRAS pathway and other signalling pathwaysSemantic proximity Read ↗

The Role of KRAS Mutations in Colorectal Cancer: Biological Insights, Clinical Implications, and Future Therapeutic PerspectivesSemantic proximity Read ↗

RAS and BRAF genes as biomarkers and target for personalised colorectal cancer therapy: An update.Semantic proximity Read ↗

KRAS mutations in metastatic colorectal cancer: from a de facto ban on anti-EGFR treatment in the past to a potential biomarker for precision medicine.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.